Twist2 contributes to cisplatin-resistance of ovarian cancer through the AKT/GSK-3β signaling pathway

Cisplatin is regularly used in the treatment of ovarian cancer. However, the drug only provides a modest survival advantage, primarily due to chemoresistance and the upregulation of antiapoptotic machineries in ovarian cancer cells. Therefore, targeting the mechanisms responsible for cisplatin resis...

Descripción completa

Detalles Bibliográficos
Autores principales: WANG, TIAN, LI, YAN, TUERHANJIANG, ABIDAN, WANG, WENWEN, WU, ZHANGYING, YUAN, MING, MAITITUOHETI, MAYINUER, WANG, SHIXUAN
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2014
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3961411/
https://www.ncbi.nlm.nih.gov/pubmed/24944676
http://dx.doi.org/10.3892/ol.2014.1816

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3961411/
https://www.ncbi.nlm.nih.gov/pubmed/24944676
http://dx.doi.org/10.3892/ol.2014.1816

Ejemplares similares